FCPA Pharmaceutical Bribery: Prescribing, Promotion, and Government Doctors

FCPA pharmaceutical bribery buys a foreign public official’s influence over prescriptions, drug purchasing, or market access through payments and other benefits. A congress invitation, a clinical study, or a consulting agreement can carry the inducement. If you work in sales, medical affairs, or finance, you may recognize the connection between the doctor selected, the benefit approved, and the business expected in return.

What Pharmaceutical Bribery Buys From a Public Hospital

A pharmaceutical company’s customer can also be the foreign official controlling public business: a doctor, pharmacist, or hospital administrator. The decision can concern which drug to prescribe, which purchase to approve, or which products the institution will use. That puts the prescribing target beside the sponsorship approval, and the payment’s purpose beside its description in the accounts.

In pharmaceutical-industry remarks delivered in March 2015, the Securities and Exchange Commission’s enforcement director identified recurring cases involving payments for prescriptions, access to formularies, and bribes disguised as charitable contributions. A formulary or government reimbursement list can determine which drugs receive institutional support. The commercial decision can therefore sit upstream of the individual prescription, with the person controlling that list.

Those remarks also described pharmaceutical companies’ contact with customs, licensing, and inspection officials. Perishable medicines awaiting clearance put the logistics team in contact with government decision-makers too. The employee handling a shipment delay may know which decision an intermediary was being paid to influence, while sales knows which hospital is waiting for the product.

Congress Sponsorship Tied to Prescription Targets

Under its 2020 deferred prosecution agreement with the Justice Department, Novartis Hellas admitted sponsoring Greek public-sector ophthalmologists’ attendance at medical congresses in exchange for increased Lucentis prescribing. The admitted conduct covered 2012 through 2015. The sponsorship entered advertising or promotional accounts that fed into the parent company’s books.

The Commission’s separate order against Novartis AG required the company to return $92,300,000 in profits. It alleged that employees ranked healthcare professionals by prescribing preference and volume. Benefits became investments, and sales and marketing staff planned around the expected return. Doctors who failed to deliver the expected prescriptions could lose the benefits. The SEC quoted a manager’s action plan:

We see a sales target dressed as medical education: the prescription was the return owed on the gift. The conference itself took place, while the sales plan measured what the sponsored doctor would prescribe. That comparison gives the purpose of a travel benefit a concrete business history, from the person selected to the result the company expected.

The enforcement director’s speech described a different way of rewarding prescribing in the SEC’s case against Pfizer. In China, the agency alleged that government doctors accumulated points based on their Pfizer prescriptions and redeemed them for gifts, including cell phones and tea sets. The gift could change while the prescription count remained the measure of the reward. A points schedule makes that exchange unusually easy to see.

Clinical Studies That Paid for Prescribing

Study payments can reward prescribing through a research budget. Novartis Hellas admitted in its criminal agreement that the EXACTLY study was repurposed to increase prescriptions. A study file and a sales plan could describe the same doctor for very different reasons.

In its settled order, the SEC alleged that 25,500 of the 42,000 clinical research forms contained mistakes. It also described an audio recording of a study debrief in which employees showed they knew some participating doctors regarded the payments as rewards for prescriptions. The errors and the recorded discussion put the study’s stated purpose beside what employees understood the money to be buying.

The SEC further alleged that Novartis Greece used dummy vendors to track which doctors received study payments and to monitor spending against the approved budget. For a medical-affairs employee, the revealing records include the work the study produced and how participants were selected. For someone in finance, the vendor record may explain how the same doctor’s payments were tracked under a different label.

In its 2018 order resolving accounting charges, the Commission alleged that Sanofi paid a doctor at a large public hospital in Jordan consulting, speaking, and clinical-trial fees. The doctor also sat on the hospital’s tender committee. According to the order, medical affairs approved the clinical-trial fees, yet the doctor never provided reports of findings or observations. Sanofi allegedly paid consulting and clinical-trial fees by check to an unrelated person at the doctor’s request.

The comparison reaches beyond whether an approval box was checked. Who selected the doctor, what work arrived, who received the money, and what purchasing authority the doctor held explain far more about the transaction.

Medical Journals as Payment Channels

A journal can stand between a pharmaceutical company’s payment and the doctor it wants to influence. The Novartis SEC order alleged that Korean sales personnel selected doctors for editorial and roundtable meetings organized through medical journals. Some meetings included product promotion by sales representatives and recreational activities afterward.

According to the order, Novartis Korea paid journals more than $16.3 million between 2011 and 2015, some of which passed to doctors as improper honoraria. The Commission said advertising fees funded the honoraria and concealed them in the accounts. Advertising. For payments to doctors. It alleged that the vendor arrangements also bypassed the required compliance review. The invoice and participant list connect the journal to the doctors further along the payment route.

The SEC described another Korean study funded with $100,000, involving 17 doctors selected in advance. According to the order, Novartis supplied their names to a medical journal, booked the funding as advertising, and failed to obtain the required medical-affairs review. Someone seeing only the invoice would miss how the doctors were chosen.

Government Doctors Who Control Tenders and Patients

Public doctors can influence patient referrals and purchasing as well as prescriptions. Fresenius Medical Care’s dialysis business provides a parallel: the Commission alleged that payments to public doctors bought influence over equipment purchases and patient flow.

The SEC’s 2019 order alleged that its Turkish business gave publicly employed doctors joint-venture shares in exchange for directing patients from public institutions to Fresenius clinics. According to the order, the doctors contributed no capital for those shares. The civil resolution required Fresenius to return $135,000,000 in profits from the conduct covered by the order.

The same order alleged that Fresenius Spain supplied a public-hospital doctor with draft tender specifications, a proposed scoring method, and proposed scores. According to the Commission, the doctor agreed to some proposals through a personal email account, and Fresenius won the tender. The valuable connection for an insider is between the company’s draft and the purchasing process the public institution was supposed to control.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA emphasizes how employees circumvented controls as payment schemes evolved. The Commission’s Serbian account makes that point concrete: after compliance prohibited an agent, an executive allegedly approved payments through a transport vendor that then paid the doctors. In that account, the change of vendor preserved the payment route to its intended recipients. For someone who raised the original concern, what happened after the prohibition is part of the story.

Charitable Benefits Tied to Government Orders

Charitable support can buy influence over public purchasing. Under its non-prosecution agreement with the Justice Department, Fresenius admitted a Saudi payment scheme involving government doctors, a doctor-linked charity, and sham consulting. Employees cashed checks to themselves and handed over the money, which entered the accounts as project marketing expenses or collection commissions.

The SEC’s separate order described a charity established by a senior Saudi official whose chief executive was a doctor. According to the order, the charity had substantial influence over Ministry of Health tender awards. A general manager’s email reported that the doctor had linked support for the charity to receiving ministry orders. The Commission alleged that the doctor and his family also received travel with no business purpose.

That account gives a charitable payment a commercial context. The connection runs through the official relationship, the pending government business, and the communication linking support to orders. A person who handled the donation may know one part of that connection, while someone who handled the tender may know the other.

Distributors, Discounts, and False Consulting Entries

Distributor discounts and credit notes can supply the money for a payment while keeping the doctor’s name off the manufacturer’s expense entry. In the Kazakhstan portion of Sanofi’s settled order, the SEC alleged that managers and distributors used discounts and credits to create funds for public-tender bribes. According to the Commission, distributors returned the designated money to Sanofi employees, who delivered it to officials. Internal spreadsheets tracked the returned funds as “marzipans.” We see a confectionery name for money earmarked to buy public contracts.

The Novartis order described another route involving Alcon’s Vietnam business and its distributor. The SEC alleged that the distributor paid doctors to recommend Alcon products, with approval from Alcon managers and employees. According to the order, Alcon reimbursed up to 50% of the payment costs through credit notes. The order described the reimbursements as falsely recorded consulting payments in Novartis’s consolidated books.

The same public-company accounting obligation reaches payments to private healthcare professionals. In Sanofi’s Gulf operations, the SEC alleged that sales staff submitted false receipts for roundtable meetings that never happened. Managers allegedly approved the reimbursements, pooled the returned cash, and used it to pay private doctors to increase prescriptions. The order resolved books-and-records and accounting-controls charges.

Sanofi’s civil resolution required it to return USD 17,531,666 in profits and pay a USD 5,000,000 penalty. The Commission attributed approximately USD 11,580,099 in profits to the Kazakhstan conduct alone. We see a penalty smaller than the alleged profits in just one part of the case, even before the other countries enter the picture.

For a finance or accounting employee, the link may be visible in a credit note, an expense reimbursement, or a second spreadsheet. The official expense account tells one story about why the company spent the money. The sales instructions and onward payment can tell the rest.

What the Different Departments Can Connect

The strongest evidence connects the business decision to the benefit and its accounting. The Novartis, Fresenius, and Sanofi accounts show why colleagues in different departments can hold complementary pieces:

• Sales and promotion: prescribing rankings, sponsorship selections, expected returns, and messages changing benefits when the doctor delivers less business.
• Medical affairs and study teams: participant selection, clinical forms, missing reports, and whether the work received the required review.
• Tender and clinic teams: public-hospital roles, draft specifications, scoring proposals, patient referrals, and the business expected in return.
• Finance and distribution: vendor identities, discount approvals, credit notes, checks, expense claims, and the accounts used to describe them.
• Compliance and audit: the original concern, the response, and whether a prohibited payment continued through another vendor.

These connections give an insider’s knowledge its value. A person who attended the study debrief can explain what employees understood the payments to mean. A person who handled the vendor change can explain why a transport company started paying doctors. We work with that knowledge to understand who made the decisions and how the payments served the business.

How FCPA Whistleblowers Are Rewarded

The Securities and Exchange Commission’s whistleblower award program can pay eligible whistleblowers a combined 10% to 30% of qualifying sanctions collected. For an insider who knows about pharmaceutical bribery under the Foreign Corrupt Practices Act, we assess the award path against the company, payments, and conduct you know.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That concerns fraud against the government, a separate basis from foreign-bribery enforcement. If your pharmaceutical matter also involves a domestic health care payment problem, we assess that connection with you.

You Know Why the Doctor Was Selected

If you recognize a prescribing target behind a congress invitation, a study payment, or a distributor credit, talk with our whistleblower experts about what you saw. We connect your knowledge of the pharmaceutical business to a case strategy and bring in FCPA whistleblower lawyers who understand public hospital purchasing and concealed payments. We stay with you through the whole journey to build your strongest pharmaceutical bribery whistleblower case.